Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents (2016 - 2025)

AC Immune (ACIU) has disclosed Cash & Equivalents for 9 consecutive years, with $41.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents fell 53.17% to $41.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $41.4 million, a 53.17% decrease, with the full-year FY2024 number at $41.4 million, down 52.59% from a year prior.
  • Cash & Equivalents was $41.4 million for Q4 2024 at AC Immune, down from $88.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $178.0 million in Q4 2020 to a low of $32.8 million in Q4 2022.
  • A 5-year average of $86.0 million and a median of $88.5 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 63.23% in 2022, then soared 169.9% in 2023.
  • AC Immune's Cash & Equivalents stood at $178.0 million in 2020, then tumbled by 49.9% to $89.2 million in 2021, then crashed by 63.23% to $32.8 million in 2022, then skyrocketed by 169.9% to $88.5 million in 2023, then plummeted by 53.17% to $41.4 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Cash & Equivalents are $41.4 million (Q4 2024), $88.5 million (Q4 2023), and $32.8 million (Q4 2022).